Interim report 2026
Filed with HKEX · Stock code 2616 · · 98 pages · English
Summary by 6ix AI
The report indicates significant revenue growth driven by increased sales of pharmaceutical products, particularly following the inclusion of pralsetinib in a national reimbursement list. The report also outlines ongoing research and development efforts and strategic partnerships aimed at enhancing its market presence.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CStone Pharmaceuticals
- Voluntary announcement - increase in shareholding by CEO and executive director dr. jianxin yang by 496,000 shares, with accumulated purchase totaling 14,210,500 shares
- CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
- CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
- CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
- ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
Later from CStone Pharmaceuticals
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - cstone announces major clinical validation milestone for CS2009 at ESMO 2026: data from more than 300 patients support mechanism, safety and broad antitumor activity
- Voluntary announcement - cstone and kimia therapeutics enter clinical development collaboration to advance a novel drug candidate targeting repair pathways critical for solid tumor survival
- Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
- Grant of share options and restricted share units
Follow CStone Pharmaceuticals into a list and get an email when it puts out news.
Follow CStone Pharmaceuticals